Diabetes Research

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

The move pauses development of a once‑daily GLP‑1/GIP dual agonist after a 16‑week trial showed A1C reductions, meaningful weight loss, and lower insulin needs.